Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.

ABSTRACT:

Objectives

Two oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively. The aim of this study were to determine the trends in lung cancer burden and examine changes in lung cancer-related survival rates and mortality following the launch of these new drugs.

Setting

Yearly lung cancer-related data (1994-2013), including incidence, number of newly diagnosed patients, survival rate and mortality, were retrieved from the Taiwan Cancer Registry Database.

Design and outcome measures

Using a time series design with autoregressive integrated moving average model, we investigated and projected trends in the incidence and early

SUBMITTER: Hsu JC 

PROVIDER: S-EPMC7223022 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature